Nexalin Technology, Inc. (NXL) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Medical - Devices industria. La empresa tiene su sede en Houston, TX, United States. El CEO actual es Mark White.
NXL tiene fecha de IPO 2022-09-16, 6 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $8.5M.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
